Loading...
SLNO logo

Soleno Therapeutics, Inc.NasdaqCM:SLNO Stock Report

Market Cap US$2.8b
Share Price
US$53.01
US$113.54
53.3% undervalued intrinsic discount
1Y-29.9%
7D0.1%
Portfolio Value
​
View

Soleno Therapeutics, Inc.

NasdaqCM:SLNO Stock Report

Market Cap: US$2.8b

Soleno Therapeutics (SLNO) Stock Overview

Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. More details

SLNO fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance3/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 87.5% below our estimate of its fair value

Earnings are forecast to grow 33.56% per year

Became profitable this year

Risk Analysis

Volatile share price over the past 3 months compared to the US market

Significant insider selling over the past 3 months


SLNO Community Fair Values

Create Narrative

See what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

View all narratives

Soleno Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Soleno Therapeutics
Historical stock prices
Current Share PriceUS$53.01
52 Week HighUS$90.32
52 Week LowUS$29.43
Beta-2.22
1 Month Change0.44%
3 Month Change37.69%
1 Year Change-29.86%
3 Year Change905.88%
5 Year Change246.47%
Change since IPO-82.37%

Recent News & Updates

Recent updates

Seeking Alpha • Mar 21

Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory

Summary Soleno Therapeutics is nearing FDA approval for its lead drug, DCCR, targeting Prader-Willi Syndrome, a rare genetic condition with no current FDA-approved treatments. Despite positive analyst ratings and a strong cash position, insider selling and competition from companies like Aardvark Therapeutics and Acadia Pharmaceuticals raise concerns. The PWS market is valued at $600 million, but Soleno's $2.2 billion market cap seems inflated given its limited pipeline and looming competition. An analysis around Soleno Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Analysis Article • Feb 26

We're Hopeful That Soleno Therapeutics (NASDAQ:SLNO) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Nov 08

Companies Like Soleno Therapeutics (NASDAQ:SLNO) Can Afford To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 10

Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments

Summary Soleno Therapeutics' DCCR shows promising results in reducing hyperphagia in PWS patients. I believe its FDA approval is likely by December 27, 2024. DCCR could become the first approved treatment for PWS hyperphagia, addressing a significant unmet medical need. DCCR's unique mechanism targets PWS hyperphagia while preserving lean mass. This potentially extends its use beyond PWS to weight loss, enhancing SLNO's market prospects. SLNO's robust cash position and recent equity raise ensure sufficient funding for DCCR's commercialization, reducing near-term dilution risks. Despite inherent biotech and market adoption risks, SLNO's favorable regulatory outlook and first-mover advantage in treating PWS hyperphagia justify a 'Strong Buy' rating. Read the full article on Seeking Alpha
Analysis Article • Mar 08

We're Not Worried About Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn

Just because a business does not make any money, does not mean that the stock will go down. For example, Soleno...
Analysis Article • Sep 20

Here's Why We're Watching Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

SLNOUS BiotechsUS Market
7D0.1%-1.8%-0.3%
1Y-29.9%32.7%24.1%

Return vs Industry: SLNO underperformed the US Biotechs industry which returned 32.7% over the past year.

Return vs Market: SLNO underperformed the US Market which returned 24.1% over the past year.

Price Volatility

Is SLNO's price volatile compared to industry and market?
SLNO volatility
SLNO Average Weekly Movement11.5%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.2%

Stable Share Price: SLNO's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: SLNO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1999182Anish Bhatnagarsoleno.life

Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017.

Soleno Therapeutics, Inc. Fundamentals Summary

How do Soleno Therapeutics's earnings and revenue compare to its market cap?
SLNO fundamental statistics
Market capUS$2.76b
Earnings (TTM)US$95.63m
Revenue (TTM)US$285.01m
28.9x
P/E Ratio
9.7x
P/S Ratio

Is SLNO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SLNO income statement (TTM)
RevenueUS$285.01m
Cost of RevenueUS$3.90m
Gross ProfitUS$281.11m
Other ExpensesUS$185.48m
EarningsUS$95.63m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)1.83
Gross Margin98.63%
Net Profit Margin33.55%
Debt/Equity Ratio10.1%

How did SLNO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/18 14:37
End of Day Share Price 2026/05/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Soleno Therapeutics, Inc. is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Kristen KluskaCantor Fitzgerald & Co.
François BriseboisCraig-Hallum Capital Group LLC